Table 1.
Baseline demographic and clinical characteristics in severely ill patients
| Anidulafungin (n = 89) |
Fluconazole (n = 74) |
|
|---|---|---|
| Age (years), mean (SD) | 60.2 (16.4) | 62.2 (16.4) |
| APACHE II score, mean (SD) | 18.0 (7.0) | 17.3 (6.8) |
| Gender, n (%) | ||
| Male | 45 (50.6) | 41 (55.4) |
| Female | 44 (49.4) | 33 (44.6) |
| Race, n (%) | ||
| White | 65 (73.0) | 59 (79.7) |
| Black | 19 (21.3) | 9 (12.2) |
| Other | 5 (5.6) | 6 (8.1) |
| Absolute neutrophil count, n (%) | ||
| ≤ 500 | 3 (3.4) | 4 (5.4) |
| > 500 | 86 (96.6) | 70 (94.6) |
| Risk factors for candidemia, n (%) | ||
| Central venous catheter | 71 (79.8) | 58 (78.4) |
| Broad-spectrum antibiotics | 65 (73.0) | 53 (71.6) |
| Recent surgery | 37 (41.6) | 34 (45.9) |
| Recent hyperalimentation (TPN) | 25 (28.1) | 16 (21.6) |
| Malignancy | 23 (25.8) | 16 (21.6) |
| Immunosuppressive therapy | 14 (15.7) | 19 (25.7) |
| Transplant | 5 (5.6) | 4 (5.4) |
| Source of isolates, n (%) | ||
| Candidemia | 85 (95.5) | 69 (93.2) |
| Intra-abdominal infection | 4 (4.5) | 5 (6.8) |
| Candida spp., n (%) | ||
| Single isolate | 81 (91.0) | 69 (93.2) |
| C. albicans | 45 (50.6) | 43 (58.1) |
| C. glabrata | 15 (16.9) | 14 (18.9) |
| C. parapsilosis | 10 (11.2) | 4 (5.4) |
| C. tropicalis | 9 (10.1) | 6 (8.1) |
| Mixed | 8 (9.0) | 5 (6.8) |
APACHE, Acute Physiology and Chronic Health Evaluation; SD, standard deviation; TPN, total parenteral nutrition.